2016 - 2022 Publications

2022

• “When States Step Up:  California and the Case for State-Led Insulin Manufacturing”
  Mariana Socal, Vishaal Pegany, Mark Ghaly
  Annals of Internal Medicine, November 2022
   
• “The Price Paradox of Biosimilar-Like Long-Acting Insulin”
  Morgane Mouslim, Emaan Rashidi, Joseph Levy, Mariana Socal, Antonio Trujillo
  American Journal of Managed Care, November 2022
   
• "Developing Prioritization Criteria to Identify Target Drugs for CalRx the California Generic Drugs Initiative"
  Mariana Socal, Emily Estus, Jingmiao Long, Matthew Crane, Vishaal Pegany, Gerard Anderson
  Value in Health:  The Journal of the International Society for Pharmacoeconomics and Outcomes Research, November 2022
   
• "Estimating Savings Opportunities From Therapeutic Substitutions of High-Cost Generic Medications"
  Mariana Socal, Thomas Cordeiro, Gerard Anderson
  JAMA Network Open, November 2022
   
• "State-Level Policy Efforts to Regulate Pharmacy Benefit Managers (PBMs)"
  Joseph Mattingly II, Maisie Lewis, Mariana Socal, Ge Bai
  Science Direct, November 2022
   
• "Anticipating Reforms to the Prescription Drug User Fees Act"
  Jeromie Ballreich, Mariana Socal, Gerard Anderson
  JAMA Network Open, November 2022
   
• "The New Medicare Part D Out-Of-Pocket Cap Will Have Unintended Consequences.  Here's How to Address Them"
  Mariana Socal, Matthew Crane, Jeromie Ballreich, Gerard Anderson
  BMC Public Health, September 2022
   
• "Modeling the Potential Economic Benefits of an Oral SARS-CoV2 Vaccine During an Outbreak of COVID-19"
  Bryan Patenaude, Jeromie Ballreich
  Applied Health Economics and Health Policy, July 2022
   
• "Including Pharmaceuticals in Bundled Payments"
  Gerard Anderson, Andrew York, Joshua Choe
  Applied Health Economics and Health Policy, July 2022
   
• "Medicare Spending on Drugs with Accelerated Approval"
  Jeromie Ballreich, Mariana Socal, Charles Bennett, Martin Schoen, Antonio Trujillo, Andrew Xuan, Gerard Anderson
  Annuals of Internal Medicine, July 2022
   
• "Trajectories of Prices in Generic Drug Markets:  What We Can Infer From Looking at Trajectories Rather Than Average Prices?"
  Antonio Trujillo, Jose Gutierrez, Emmanual Garcia Morales, Mariana Socal, Jeromie Ballreich, Gerard Anderson
  Health Economics Review, July 2022
   
• "Medicare Advantage Coverage Restrictions for the Costliest Physician-Administered Drugs"
  Kelly Anderson, Caleb Alexander, Carolyne Ma, Sydney Dy, Aditi Sen
  American Journal of Managed Care, July 2022
   
• "Association Between Open Payments-Reported Industry Transfers of Value and Prostaglandin Analog Prescribing in the US"
  Andrew Nguyen, Kelly Anderson, Gerard Anderson
  JAMA Ophthalmology, July 2022
   
• "Drug Costs in Context:  Assessing Drug Costs in Cost-of-Illness Analyses"
  Joseph Mattingly II, Shannon Weathers
  Drugs in Context, July 2022
   
• "Opportunities and Challenges of Generic Pre-Exposure Prophylaxis Drugs for HIV"
  Jeromie Ballreich, Timothy Levengood, Rena Conti
  Cambridge Core, July 2022
   
• "Prescribing of Low- Versus High-Cost Part B Drugs in Medicare Advantage and Traditional Medicare"
  Kelly Anderson, Daniel Polsky, Sydney Dy, Aditi Sen
  Health Services Research, June 2022
   
• "Trends of Prescription Drug Manufacturer Rebates in Commercial Health Insurance Plans, 2015-2019"
  Elizabeth Plummer, Mariana Socal, Jeromie Ballreich, Gerard Anderson, Ge Bai
  JAMA Health Forum, May 2022
   
• "Ensuring a High-Quality and Resilient Supply Chain of Essential Medications Means Paying More"
  Joseph Mattingly II, Rena Conti
  Journal of Managed Care - Specialty Pharmacy, May 2022
   
• "Reply To:  The Informed Majority Could Help Make Research Into Alzheimer's Disease Fairer and More Efficient"
  Michael DiStefano, Caleb Alexander, Gerard Anderson
  Journal of the American Geriatrics Society, March 2022
   
• "Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019"
  SM Qasim Hussaini, Arjun Gupta, Kelly Anderson, Jeromie Ballreich, Lauren Hersch Nicholas, Caleb Alexander
  JAMA Network Open / Research Letter / Health Policy, March 2022
   
• "Effects of an Out-of-Pocket Maximum in Medicare Part D "
  Sonal Parasrampuria, Gerard Anderson
  American Journal of Managed Care, February 2022
   
• "Public Opinion Regarding US Food and Drug Administration Approval of Aducanumab and Potential Policy Responses:  A Nationally Representative Survey"
  Michael DiStefano, Caleb Alexander, Daniel Polsky, Gerard Anderson
  Journal of the American Geriatrics Society, February 2022
   
• "Innovation in the U.S. Health Care System's Organization and Delivery"
  Michael DiStefano, So-Yeon Kang, Mariana Socal, Gerard Anderson
  The School of Public Policy Publications / SPP Research Paper, January 2022
   
• "Coverage of Genetic Therapies for Spinal Muscular Atrophy Across Fee-For-Service Medicaid Programs"
  Jeromie Ballreich, Ijeamaka Ezebilo, Banda Khalifa, Joshua Choe, Gerard Anderson
  Journal of Managed Care / Specialty Pharmacy, January 2022
   

2021

• "Participation, Pricing, and Enrollment in a Health Insurance “Public Option”:  Evidence From Washington State's Cascade Care Program"
  Aditi Sen, Yashaswini Singh, Mark Meiselbach, Matthew Eisenberg, Gerard Anderson
  The Millbank Quarterly, November 2021
   
• "Association Between Waste-Free Formularies and Prescription Drug Spending Among Self-insured Employers"
  Mariana Socal, Ge Bai, Thomas Cordeiro, Gerard Anderson
  JAMA Network Open, October 2021
   
• "Medicare Expenditures of Atezolizumab for a Withdrawn Accelerated Approved Indication"
  Jeromie Ballreich, Charles Bennet, Thomas Moore, Caleb Alexander
  JAMA Oncology, October 2021
   
• "Biosimilar Uptake of Filgrastim and Impact on Spending in Medicare Part D From 2015 to 2019"
  Syed Hussaini, Arjun Gupta, Kelly Anderson, Jeromie Ballreich, Lauren Nicholas, Caleb Alexander
  Journal of Clinical Oncology, September 2021
   
• "Economic Value of Vaccines to Address the COVID-19 Pandemic:  A U.S. Cost-effectiveness and Budget Impact Analysis"
  William Padula, Shreena Malaviya, Natalie Reid, Benjamin Cohen, Francine Chingcuanco, Jeromie Ballreich
  Journal of Medical Economics, August 2021
   
• "Legal Obstacles to Biosimilar Market Entry"
  Laura Karas, Rachel Sachs, Gerard Anderson
  HPHR Journal / Harvard Public Health Review (Edition 28 General), August 2021
   
• "Factors Associated With Manufacturer Drug Coupon Use at US Pharmacies"
  So-Yeon Kang, Aditi Sen, Joseph Levy, Jingmiao Long, Caleb Alexander, Gerard Anderson
  JAMA Health Forum, August 2021
   
• "Hospital Inpatient Charges of COVID-19 Diagnostic Tests Ranged from $10 to $1390"
  Hossein Zare, Ge Bai, Corey Albrecht, Joshua Choe, Gerard Anderson
  Population Health Management, August 2021
   
• "Comparison of Trends in Nonprofit Hospitals’ Charity Care Eligibility Policies Between Medicaid Expansion States and Medicaid Nonexpansion States"
  Ge Bai, Hossein Zare, Matthew Eisenberg, Daniel Polsky, Gerard Anderson
  Medical Care Research and Review, August 2021
   
• "Bipartisan Federal Legislation to Address Insulin Access and Affordability"
  Mariana Socal, Ge Bai
  Diabetes Spectrum, July 2021
   
• "Large Self-insured Employers Lack Power to Effectively Negotiate Hospital Prices"
  Matthew Eisenberg, Mark Meiselbach, Ge Bai, Aditi Sen, Gerard Anderson
  American Journal of Managed Care, July 2021
   
• "Changes Associated with the Entry of a Biosimilar in the Insulin Glargine Market"
  Joseph Levy, Zahra Chowdhury, Mariana Socal, Antonio Trujillo
  JAMA Internal Medicine, June 2021
   
• "Ultra-Expensive Drugs And Medicare Part D: Spending And Beneficiary Use Up Sharply"
  So-Yeon Kang, Daniel Polsky, Jodi Segal, Gerard Anderson
  Health Affairs, June 2021
   
• "Cost-effectiveness of Total State Coverage for Hepatitis C Medications"
  William Padula, Jonathan Levin, Joy Lee, Gerard Anderson
  American Journal of Managed Care, May 2021
   
• "Variability of COPD Inhaler Coverage in Medicare Part D"
  Benjamin Wormser, Mariana Socal, Gerard Anderson
  American Journal of Managed Care, May 2021
   
• "Labor Market Concentration and Worker Contributions to Health Insurance Premiums"
  Mark Meiselbach, Matthew Eisenberg, Ge Bai, Aditi Sen, Gerard Anderson
  Medical Care Research and Review, May 2021
   
• "Manufacturer-Sponsored Cost-Sharing Programs for Insulin:  Are Patients Getting the Help They Need?"
  J. Hunter Fraker, Mariana Socal
  Journal of General Internal Medicine, May 2021
   
• "Willingness to Follow Mask Mandates Increases Over Two-Month Period"
  Joshua Choe, Antonio Trujillo, Gerard Anderson
  Population Health Management, April 2021
   
• "The Pandemic and the Supply Chain:  Gaps in Pharmaceutical Production and Distribution"
  Mariana Socal, Joshua Sharfstein, Jeremy Greene
  American Journal of Public Health, April 2021
   
• "Frequency and Costs of Out-of-Network Bills for Outpatient Laboratory Services Among Privately Insured Patients"
  Aditi Sen, Mark Meiselbach, Yang Wang, Matthew Eisenberg, Gerard Anderson
  JAMA Internal Medicine, April 2021
   
• "A Non-Profit Approach to Address Foreign Dependence of Generic Drugs"
  Dan Liljenquist, Ge Bai, Ameet Sarpatwari, Gerard Anderson
  Cambridge University Press, April 2021
   
• "Factors Associated With Prescriptions for Branded Medications in the Medicare Part D Program"
  Mariana Socal, Ge Bai, Gerard Anderson
  JAMA Network Open, March 2021
   
• "Characteristics of Copayment Offsets for Prescription Drugs in the United States"
  Aditi Sen, So-Yeon Kang, Emaan Rashidi, Devoja Ganguli, Gerard Anderson, Caleb Alexander
  JAMA Internal Medicine, March 2021
   
• "The Role of Advance Purchasing Commitments in Government Drug Price Negotiations:  Lessons From the COVID-19 Response"
  Mariana Socal, Gerard Anderson
  American Public Health Association, March 2021
   
• "Assessing the Added Therapeutic Benefit of Ultra-Expensive Drugs"
  Michael DiStefano, So-Yeon Kang, Farah Yehia, Christian Morales, Gerard Anderson
  Value In Health / Health Policy Analysis, March 2021
   
• "The Association Between Drug Approvals and Burden of Disease From 1990 to 2017"
  Tarun George, Jeromie Ballreich, Antonio Trujillo, Gerard Anderson
  Journal of General Internal Medicine, February 2021
   
• "Biosimilar Formulary Placement in Medicare Part D Prescription Drug Plans:  A Case Study of Infliximab"
  Mariana Socal, Ijeamaka Ezebilo, Ge Bai, Gerard Anderson
  American Society of Health-System Pharmacists, February 2021
   
• "Off-Label Coverage of High-Cost Drugs by Independent Charity Patient Assistance Programs"
  So-Yeon Kang, Mariana Socal, Ge Bai, Gerard Anderson
  Journal of General Internal Medicine, February 2021
   
• "Allocation of National Institutes of Health Funding by Disease Category in 2008 and 2019"
  Jeromie Ballreich, Cary Gross, Neil Powe, Gerard Anderson
  JAMA Network, January 2021
   

2020

• "Payment Incentives and the Use of Higher-Cost Drugs:  A Retrospective Cohort Analysis of Intravenous Iron in the Medicare Population"
  Bryan Hambley, Kelly Anderson, Satish Shanbhag, Aditi Sen, Gerard Anderson
  American Journal of Managed Care, December 2020
   
• "Fairness in the Trade-Off Between Drug Price Regulation and Investments in Research and Development:  A Survey of Economists"
  Taruja Karmarkar, Antonio Trujillo, William Padula, Jeremy Green, Caleb Alexander, Gerard Anderson
  Journal of Behavioral Economics for Policy, December 2020
   
• "Assessment of Availability, Clinical Testing, and US Food and Drug Administration Review of Biosimilar Biologic Products"
  Thomas Moore, Morgane Mouslim, Jenna Blunt, Caleb Alexander, Kenneth Shermock
  JAMA Internal Medicine, October 2020
   
• "Association Between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products"
  Morgane Mouslim, Antonio Trujillo, Caleb Alexander, Jodi Segal
  Value in Health, October 2020
   
• "Barriers to Biosimilar Utilization in the United States"
  Stacy Dalpoas, Mariana Socal, Celia Proctor, Kenneth Shermock
  American Journal of Health-System Pharmacy, October 2020
   
• "Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the U.S."
  William Padula, Sonal Parasrampuria, Mariana Socal, Rena Conti, Gerard Anderson
  PharmacoEconomics, October 2020
   
• "Modifying the Criteria for Granting Orphan Drug Market Exclusivity"
  Mariana Socal, Sonal Parasrampuria, Gerard Anderson
  Value in Health, September 2020
   
• "Comparing Patient OOP Spending for Specialty Drugs in Medicare Part D and Employer-Sponsored Insurance"
  Sonal Parasrampuria, Aditi Sen, Gerard Anderson
  American Journal of Managed Care, September 2020
   
• "Predictors of Orphan Drug Coverage Restrictions in Medicare Part D"
  Farah Yehia, Jodi Segal, Gerard Anderson
  American Journal of Managed Care, September 2020
   
• "Critical Drugs for Critical Care:  Protecting the U.S. Pharmaceutical Supply Chain in Public Health Crises"
  Mariana Socal, Joshua Sharfstein, Jeremy Greene
  American Journal of Public Health, August 2020
   
• "Abandoning List Prices in Medicaid Drug Reimbursement Did Not Impact Spending"
  Benedic Ippolito, Joseph Levy, Gerard Anderson
  Health Affairs, July 2020
   
• "PPE Supply Chain Needs Data Transparency and Stress Testing"
  Tinglong Dai, Ge Bai, Gerard Anderson
  Journal of General Internal Medicine, June 2020
   
• "How Much Could Be Saved by Requiring Companies to Refund Tax Incentives on Highly Profitable Orphan Drugs?"
  Farah Yehia, Caleb Alexander, Gerard Anderson
  Value in Health, May 2020
   
• "Variation in the Estimated Costs of Pivotal Clinical Trials Supporting the U.S. Approval of New Therapeutic Agents, 2015-2017:  A Cross-Sectional Study"
  Thomas Moore, James Heyward, Gerald Anderson, Caleb Alexander
  BMJ Open Science, May 2020
   
• "A Review of the United States’ Naming Convention for Biological Products"
  Jacqueline Saunders, Celia Proctor, Kenneth Shermock
  Pharmacoepidemiology and Drug Safety, April 2020 (Published Online)
   
• "Diagnostic Testing for the Novel Coronavirus"
  Joshua Sharfstein, Scott Becker, Michelle Mello
  JAMA, 323.15, 2020: 1437-1438
   
• “A Bold Response to the Covid-19 Pandemic: Medical Students, National Service, and Public Health”
  Howard Bauchner, Joshua Sharfstein
  JAMA, 2020
   
• "Performance and Priorities: A Cross-Sectional Study of Local Health Department Approaches to Essential Public Health Services"
  Megan Wallace, Joshua Sharfstein, Justin Lessler
  Public Health Reports, December 2019
   
• "Affording Genetic Therapies in the Medicaid Program"
  Jeromie Ballreich, Ijeamaka Ezebilo, Joshua Sharfstein
  JAMA Pediatrics, April 2020
   
• "Estimated Costs of Pivotal Trials for U.S. Food and Drug Administration-Approved Cancer Drugs, 2015-2017"
  Emily Han-Chung Hsiue, Thomas Moore, Caleb Alexander
  Clinical Trials, February 2020 
   
• "Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim"
  Mariana Socal, Kelly Anderson, Aditi Sen, Ge Bai, Gerard Anderson
  Value in Health, April 2020
   
• "Interchangeable Insulins - New Pathways for Safe, Effective, Affordable Diabetes Therapy"
  Mariana Socal, Jeremy Greene
  New England Journal of Medicine, March 2020
   
• "Off-Label Coverage of High-Cost Drugs by Independent Charity Patient Assistance Programs"
  SoYeon Kang, Mariana Socal, Ge Bai, Gerard Anderson
  Journal of General Internal Medicine, February 2020
   
• "Older Americans' Preferences Between Lower Drug Prices and Prescription Drug Plan Choice, 2019"
  Mariana Socal, Gerard Anderson
  American Journal of Public Health, March 2020
   
• "Comparative Approaches to Drug Pricing"
  SoYeon Kang, Ge Bai, Michael DiStefano, Mariana Socal, Farah Yehia, Gerard Anderson
  Annual Review Public Health, April 2020
   
• "Patient Selection After Mandatory Bundled Payments for Hip and Knee Replacement: Limited Evidence of Lemon-Dropping or Cherry-Picking"
  CJ Humbyrd, SS Wu, Antonio Trujillo, Mariana Socal, Gerard Anderson
  Journal of Bone and Joint Surgery American, February 2020
   
• "Naming Convention, Interchangeability, and Patient Interest in Biosimilars"
  Mariana Socal, Jace Garrett, William Tayler, Ge Bai, Gerard Anderson
  Diabetes Spectrum, March 2020
   
• "Do Mergers and Acquisitions Improve Firms' Financial Performance?  The case of the U.S. Generic Drug Industry"
  Antonio Trujillo, Emmanuel Garcia, Gabriel Kabarriti, Gerard Anderson
  Journal Managerial and Decision Economics, 2020
   
• "Older Americans' Preferences Between Lower Drug Prices and Prescription Drug Plan Choice, 2019"
  Mariana Socal, Gerard Anderson
  American Journal of Public Health, March 2020 
   
• "A Review of the United States' Naming Convention for Biological Products"
  Jacqueline Saunders, Celia Proctor, Kenneth Shermock
  Pharmacoepidemiology and Drug Safety, March 2020 
   
• "Legal Strategies for Reining in 'Unconscionable' Prices for Prescription Drugs"
  Michelle Mello, Rebecca Wolitz
  Northwestern University Law Review, January 2020 
   
• "Fairness in Drug Prices:  Do Economists Think Differently From the Public?"
  Antonio Trujillo, Taruja Karmarkar, Caleb Alexander, William Padula, Jeremy Greene, Gerard Anderson
  Health Economics, Policy and Law, January 2020
   

2016-2019 

• "Do Mergers and Acquisitions Improve Firms' Financial Performance?   The Case of the U.S. Generic Drug Industry"
  Antonio Trujillo, Emmanuel Garcia-Morales, Gabriel Kabarriti, Gerard Anderson
  Wiley Online Library, October 2019 (Published Online)
   
• "Consolidated Drug Purchasing Across Federal Agencies:  A Policy to Decrease Cost Sharing for Medicare Beneficiaries"
  Jonathan Levin, Jeromie Ballreich, Mariana Socal, Ge Bai, Gerard Anderson
  Journal of Health Care Finance, Summer 2019 (Published Online)
   
• "Financial Eligibility Criteria and Medication Coverage for Independent Charity Patient Assistance Programs"
  So-Yeon Kang, Aditi Sen, Ge Bai, Gerard Anderson
  JAMA Network, August 2019
   
• "Does Incorporating Cost-Effectiveness Analysis into Prescribing Decisions Promote Drug Access Equity?"
  Michael DiStefano, Jonathan Levin
  AMA Journal of Ethics, August 2019 (Published Online)
   
• "Legal Strategies for Reining in "Unconscionable" Prices for Prescription Drugs"
  Michelle Mello, Rebecca Wolitz
  SSRN, July 2019 (Published Online)
   
• "State Efforts to Lower Health Care Prices Paid by Private Insurers"
  Aditi Sen, Amber Willink, Gerard Anderson
  JAMA Network, June 2019 (Published Online)
   
• "Globalization of Clinical Trials:  Variation in Estimated Regional Costs of Pivotal Trials, 2015-2016"
  Yao Qiao, Caleb Alexander, Thomas Moore
  Clinical Trials, June 2019
   
• "Using External Reference Pricing in Medicare Part D to Reduce Drug Price Differentials With Other Countries"
  So-Yeon Kang, Michael DiStefano, Mariana Socal, Gerard Anderson
  Health Affairs, May 2019
   
• "Insulin for All:  Treatment Activism and the Global Diabetes Crisis"
  Jing Luo, Gregg Gonsalves, Jeremy Greene
  The Lancet, May 2019
   
• "Favorable Formulary Placement of Branded Drugs in Medicare Prescription Drug Plans When Generics are Available"
  Mariana Socal, Ge Bai, Gerard Anderson
  JAMA Internal Medicine, March 2019 (Published Online)
   
• "Pharmaceutical Industry Support of US Patient Advocacy Organizations:  An International Context"
  So-Yeon Kang, Ge Bai, Laura Karas, Gerard Anderson
  American Journal of Public Health, 2019
   
• "Pharmaceutical Industry Funding to Patient-Advocacy Organizations:  A Cross-National Comparison of Disclosure Codes and Regulation"
  Laura Karas, Robin Feldman, Ge Bai, So-Yeon Kang, Gerard Anderson
  Hastings International and Comparative Law Review, 2019
   
• "Consumer Responses to Price Information in Direct-to-Consumer Drug Advertising"
  Jace Garrett, William Tayler, Ge Bai, Mariana Socal, Antonio Trujillo, Gerard Anderson
  JAMA Internal Medicine, 2019
   
• "What Trump Should Actually Do About the High Cost of Drugs"
  Thomas Bollyky, Aaron Kesselheim, Joshua Sharfstein
  New York Times, 2018
   
• "Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the U.S. Food and Drug Administration"
  Thomas Moore, Hanzhe Zhang, Gerard Anderson, Caleb Alexander
  JAMA Internal Medicine, 2018
   
• "Paying for Drugs After the Medicare Part D Beneficiary Reaches the Catastrophic Limit:  Lessons on Cost Sharing from Other U.S. Policy Partnerships Between Government and Commercial Industry"
  William Padula, Jeromie Ballreich, Gerard Anderson
  Applied Health Economics and Health Policy, 2018
   
• "Fairness in Drug Prices:  Do Economists Think Differently From the Public?"
  Antonio Trujillo, Taruja Karmarkar, Caleb Alexander, William Padula, Jeremy Greene, Gerard Anderson
  Journal of Health Economics, Policy and Law, 2018
   
• "Addressing Generic-Drug Market Failures -- The Case for Establishing a Nonprofit Manufacturer"
  Ge Bai, D. Liljenquist, Gerard Anderson
  New England Journal of Medicine, 2018
   
• "Limited Distribution Networks Stifle Competition in the Generic and Biosimilar Drug Industries"
  Laura Karas, Kenneth Shermock, Celia Proctor, Mariana Socal, Gerard Anderson
  New England Journal of Medicine, 2018
   
• "Pharmaceutical Benefit Managers, Brand-Name Drug Prices, and Patient Cost Sharing" 
  Ge Bai, Aditi Sen, Gerard Anderson
  Annuals of Internal Medicine, 2018
   
• "We Have A Cure for Hepatitis C.  But the Neediest Can't Afford It.  Lousiana Wants to Change That"
  Joshua Sharfstein, Joy Lee, Rena Conti
  Vox, 2017
   
• "Branded Prescription Drug Spending:  A Framework to Evaluate Policy Options"
  Jeromie Ballreich, Caleb Alexander, Mariana Socal, Taruja Karmarkar, Gerard Anderson
  Journal of Pharmaceutical Policy and Practice, 2017
   
• "Variable Market Exclusivity Periods for Pharmaceuticals"
  Michael Hsu, Ali Thaver, Gerard Anderson
  Health Economics and Outcome Research:  Open Access, 2016
   
• "Reducing Branded Prescription Drug Prices:  A Review of Policy Options"
  Caleb Alexander, Jeromie Ballreich, Mariana Socal, Taruja Karmarkar, Antonio Trujillo, Jeremy Greene, Joshua Sharfstein, Gerard Anderson
  Pharmacotherapy, 2017
   
• "Forces Influencing Generic Drug Development in the United States:  A Narrative Review"
  Chia-Ying Lee, Xiaochan Chen, Robert Romanelli, Jodi Segal
  Journal of Pharmaceutical Policy and Practice, 2016
   
• "Cost-Effectiveness of Tyrosine Kinase Inhibitor Treatment for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States"
  William Padula, Richard Larson, Stacie Dusetzina, Jane Apperley, Rudiger Hehlmann, Michele Baccarani, Ekkehard Eigendorff, Joelle Guilhot, Francois Guilhot, et al.
  Journal of the National Cancer Institute, 2016
   
• "Pharmaceuticals and Public Health"
  Rena Conti, Rebekah Gee, Joshua Sharfstein
  Journal of the National Cancer Institute, 2016
   
• "Role of the FDA in Affordability of Off-Patent Pharmaceuticals"
  Jeremy Greene, Gerard Anderson, Joshua Sharfstein
  JAMA, 2016
   
• "Targeting Unconscionable Prescription Drug Prices -- Maryland's Anti-Price Gouging Law"
  Jeremy Greene, William Padula
  New England Journal of Medicine, 2017